

Special Issue

Cerebral Production and Action of Pro-inflammatory Cytokines

Message from the Guest Editor

The aim of this Special Issue is to better understand cytokine production and action in the brain beyond their involvement in local immune responses to an insult or infection of the central nervous system (CNS). While the majority of the work on brain cytokine production and action has historically been on pro-inflammatory cytokines such as interleukin-1, it is important to realize that cytokines comprise many different biologically-active molecules and include interferons, interleukins, and chemokines, but also adipokines, such as leptin. Thus, several new perspectives have arisen on cytokine brain production and action that surpass the domain of classic neuroimmunology and seem closer in spirit to integrative physiology and behavior. These new perspectives can be expected to give rise to new potential therapeutic avenues of pharmacological intervention strategies.

Guest Editor

Dr. Jan-Pieter Konsman

CNRS UMR 5287 Institute for Cognitive and Integrative Neurosciences in Aquitaine (INCIA), University of Bordeaux, 33076 Bordeaux, France

Deadline for manuscript submissions

closed (30 July 2021)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/44835

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)